The hemostatic system plays a critical role in processes associated with tumor progression such as extracellular matrix degradation, neo-angiogenesis, and distant metastasis.(1) Among the mechanisms associated with the activation of the coagulation system in cancer, two procoagulant factors released by tumor cells have been reported: tissue factor, which initiates the clotting cascade and a cancer procoagulant that activates factor X. Literature supports the fact that the clinical and pathological characteristics of breast cancer correlate well with plasma hemostatic biomarkers. This evidence concerns the gene F10 and cancer.